EPO for stroke therapy - Is there a future for further clinical development?
作者信息
Minnerup Jens, Wersching Heike, Schäbitz Wolf-Rüdiger
机构信息
Department of Neurology, University Hospital Münster, Albert-Schweitzer-Strasse 33, 48149 Münster, Germany.
出版信息
Exp Transl Stroke Med. 2010 May 12;2(1):10. doi: 10.1186/2040-7378-2-10.
Abstract
摘要
相似文献
1
EPO for stroke therapy - Is there a future for further clinical development?用于中风治疗的促红细胞生成素——进一步临床开发还有未来吗？
Exp Transl Stroke Med. 2010 May 12;2(1):10. doi: 10.1186/2040-7378-2-10.
2
The efficacy of erythropoietin and its analogues in animal stroke models: a meta-analysis.促红细胞生成素及其类似物在动物脑卒中模型中的疗效：一项荟萃分析。
Stroke. 2009 Sep;40(9):3113-20. doi: 10.1161/STROKEAHA.109.555789. Epub 2009 Jun 18.
3
Asymmetric dimethylarginine in response to recombinant tissue-type plasminogen activator and erythropoietin in acute stroke.急性脑卒中时重组组织型纤溶酶原激活物和促红细胞生成素治疗的反应：不对称二甲基精氨酸。
Stroke. 2013 Aug;44(8):2128-33. doi: 10.1161/STROKEAHA.113.001145. Epub 2013 Jun 20.
4
Exploring Erythropoietin and G-CSF Combination Therapy in Chronic Stroke Patients.探索促红细胞生成素与粒细胞集落刺激因子联合疗法对慢性中风患者的疗效
Int J Mol Sci. 2016 Mar 30;17(4):463. doi: 10.3390/ijms17040463.
5
Erythropoietin improves long-term neurological outcome in acute ischemic stroke patients: a randomized, prospective, placebo-controlled clinical trial.促红细胞生成素改善急性缺血性中风患者的长期神经学预后：一项随机、前瞻性、安慰剂对照临床试验。
Crit Care. 2015 Feb 25;19(1):49. doi: 10.1186/s13054-015-0761-8.
6
Delayed erythropoietin therapy improves histological and behavioral outcomes after transient neonatal stroke.延迟促红细胞生成素治疗可改善新生儿短暂性中风后的组织学和行为学预后。
Neurobiol Dis. 2016 Sep;93:57-63. doi: 10.1016/j.nbd.2016.04.006. Epub 2016 Apr 30.
7
Erythropoietin in stroke: quo vadis.卒中患者的促红细胞生成素：何去何从。
Expert Opin Biol Ther. 2010 Jun;10(6):937-49. doi: 10.1517/14712598.2010.481435.
8
Serum erythropoietin and outcome after ischaemic stroke: a prospective study.血清促红细胞生成素与缺血性卒中后的预后：一项前瞻性研究。
BMJ Open. 2016 Feb 25;6(2):e009827. doi: 10.1136/bmjopen-2015-009827.
9
Intracerebral transplantation of erythropoietin-producing fibroblasts facilitates neurogenesis and functional recovery in an ischemic stroke model.脑内移植促红细胞生成素产生的成纤维细胞可促进缺血性脑卒中模型中的神经发生和功能恢复。
Brain Behav. 2019 May;9(5):e01274. doi: 10.1002/brb3.1274. Epub 2019 Mar 28.
10
Combining Human Umbilical Cord Blood Cells With Erythropoietin Enhances Angiogenesis/Neurogenesis and Behavioral Recovery After Stroke.将人脐带血细胞与促红细胞生成素相结合可增强中风后的血管生成/神经生成及行为恢复。
Front Neurol. 2019 Apr 10;10:357. doi: 10.3389/fneur.2019.00357. eCollection 2019.
引用本文的文献
1
Hypoxemia exerts detrimental effects on the choroid plexuses and cerebrospinal fluid system in rats.低氧血症对大鼠脉络丛和脑脊液系统产生有害影响。
Fluids Barriers CNS. 2025 Mar 12;22(1):27. doi: 10.1186/s12987-024-00613-w.
2
Ameliorative effects of L. (purslane) and its active constituents on nervous system disorders: A review.马齿苋及其活性成分对神经系统疾病的改善作用：综述
Iran J Basic Med Sci. 2023 Jan;26(1):2-12. doi: 10.22038/IJBMS.2022.65764.14464.
3
Neuroprotective mechanisms of erythropoietin in a rat stroke model.促红细胞生成素在大鼠中风模型中的神经保护机制。
Transl Neurosci. 2020 May 18;11(1):48-59. doi: 10.1515/tnsci-2020-0008. eCollection 2020.
4
Mapping of brain tissue hematocrit in glioma and acute stroke using a dual autoradiography approach.使用双放射性自显影方法对脑肿瘤和急性中风的脑组织血细胞比容进行定位。
Sci Rep. 2018 Jun 29;8(1):9878. doi: 10.1038/s41598-018-28082-w.
5
The erythropoietin-derived peptide MK-X and erythropoietin have neuroprotective effects against ischemic brain damage.促红细胞生成素衍生肽MK-X和促红细胞生成素对缺血性脑损伤具有神经保护作用。
Cell Death Dis. 2017 Aug 17;8(8):e3003. doi: 10.1038/cddis.2017.381.
6
Neuroprotection for stroke: current status and future perspectives.中风的神经保护：现状与未来展望。
Int J Mol Sci. 2012;13(9):11753-11772. doi: 10.3390/ijms130911753. Epub 2012 Sep 18.
本文引用的文献
1
Combination of tissue-plasminogen activator with erythropoietin induces blood-brain barrier permeability, extracellular matrix disaggregation, and DNA fragmentation after focal cerebral ischemia in mice.组织型纤溶酶原激活物与促红细胞生成素联合应用可诱导小鼠局灶性脑缺血后血脑屏障通透性增加、细胞外基质解聚和 DNA 片段化。
Stroke. 2010 May;41(5):1008-12. doi: 10.1161/STROKEAHA.109.574418. Epub 2010 Apr 1.
2
Darbepoetin alfa and chronic kidney disease.达比泊汀α与慢性肾脏病
N Engl J Med. 2010 Feb 18;362(7):653-4; author reply 655.
3
Erythropoiesis-stimulating agents--time for a reevaluation.促红细胞生成素——是时候重新评估了。
N Engl J Med. 2010 Jan 21;362(3):189-92. doi: 10.1056/NEJMp0912328. Epub 2010 Jan 6.
4
A systematic review and meta-analysis of erythropoietin in experimental stroke.促红细胞生成素治疗实验性脑卒中的系统评价和荟萃分析
J Cereb Blood Flow Metab. 2010 May;30(5):961-8. doi: 10.1038/jcbfm.2009.267. Epub 2009 Dec 30.
5
A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease.阿法达贝泊汀治疗2型糖尿病和慢性肾病的一项试验。
N Engl J Med. 2009 Nov 19;361(21):2019-32. doi: 10.1056/NEJMoa0907845. Epub 2009 Oct 30.
6
Recombinant human erythropoietin in the treatment of acute ischemic stroke.重组人促红细胞生成素治疗急性缺血性脑卒中。
Stroke. 2009 Dec;40(12):e647-56. doi: 10.1161/STROKEAHA.109.564872. Epub 2009 Oct 15.
7
The efficacy of erythropoietin and its analogues in animal stroke models: a meta-analysis.促红细胞生成素及其类似物在动物脑卒中模型中的疗效：一项荟萃分析。
Stroke. 2009 Sep;40(9):3113-20. doi: 10.1161/STROKEAHA.109.555789. Epub 2009 Jun 18.
8
Multifunctional actions of approved and candidate stroke drugs.已批准和候选中风药物的多功能作用。
Neurotherapeutics. 2009 Jan;6(1):43-52. doi: 10.1016/j.nurt.2008.10.032.
9
Methodological quality of animal studies of neuroprotective agents currently in phase II/III acute ischemic stroke trials.目前处于急性缺血性中风试验II/III期的神经保护剂动物研究的方法学质量。
Stroke. 2009 Feb;40(2):577-81. doi: 10.1161/STROKEAHA.108.524330. Epub 2008 Dec 12.
10
Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke.急性缺血性卒中发病3至4.5小时后使用阿替普酶进行溶栓治疗。
N Engl J Med. 2008 Sep 25;359(13):1317-29. doi: 10.1056/NEJMoa0804656.
Zotero 插件